SMMT Summit Therapeutics Inc.
Price Chart
Executive Summary
Summit Therapeutics announced positive Phase III HARMONi-6 overall survival results for ivonescimab in first-line squamous NSCLC (HR 0.66, p=0.0017 vs tislelizumab+chemo) and encouraging Phase II CRC data (70.8% ORR, 100% DCR) at ASCO 2026. These data further validate ivonescimab's differentiated PD-1/VEGF bispecific mechanism and support its potential as a new standard of care in NSCLC, with a BLA PDUFA date of November 14, 2026 for the HARMONi trial in EGFR-mutant NSCLC.
Actionable Insight
These data significantly de-risk ivonescimab's clinical profile and support its potential to become a new standard in 1L NSCLC. Key catalysts ahead: HARMONi BLA PDUFA on November 14, 2026, and upcoming HARMONi-3 data readouts (SQ PFS/interim OS in 2H26, nSQ PFS in 1H27). Monitor for FDA advisory committee meeting and potential accelerated approval path.
Key Facts
- HARMONi-6 Phase III: ivonescimab+chemo reduced risk of death by 34% vs tislelizumab+chemo (HR 0.66, 95% CI 0.50-0.87, p=0.0017) in 1L squamous NSCLC
- Median OS: 27.89 months (ivonescimab) vs 23.69 months (tislelizumab); 24-month OS rates 64.7% vs 48.6%
- First Phase III trial to show statistically significant OS benefit over an anti-PD-(L)1+chemo regimen in 1L NSCLC
- Phase II CRC (AK112-206): 70.8% ORR and 100% DCR with ivonescimab+mFOLFOX6 in 1L MSS mCRC; 9-month PFS rate 76.1% at 20 mg/kg dose
- BLA for ivonescimab in EGFR-mutant NSCLC (HARMONi trial) accepted by FDA with PDUFA date of November 14, 2026
- Results published simultaneously in The Lancet; presented at ASCO 2026 Plenary Session
- Safety profile manageable: Grade 3 TRAEs 69.2% (ivonescimab) vs 58.9% (tislelizumab); similar discontinuation rates (5.3% vs 4.5%)
Financial Impact
No financial figures provided in filing. Ivonescimab is pre-revenue in Summit's license territories; potential $15B+ revenue opportunity by 2033 per company estimates (not from filing).
Risk Factors
- HARMONi-6 is a single-region China study by partner Akeso; results may not fully replicate in global HARMONi-3 trial
- Higher Grade 3 TRAE rate (69.2% vs 58.9%) and VEGF-related hemorrhage (2.6% Grade 3+ vs 0.8%) warrant monitoring
- Ivonescimab not yet approved in any Summit license territory; regulatory and commercial execution risks remain
- Competitive landscape includes established PD-1 inhibitors and emerging bispecifics
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001599298-26-000043 |
| Document: a20260601ascoupdatecalld.htm | 0001599298-26-000043 |
| Document: ivonescimab-withxchemoth.htm | 0001599298-26-000043 |
| Document: encouraging-globalxphase.htm | 0001599298-26-000043 |
| Document: 0001599298-26-000043-index-headers.html | 0001599298-26-000043 |
| Document: 0001599298-26-000043-index.html | 0001599298-26-000043 |
| Document: 0001599298-26-000043.txt | 0001599298-26-000043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
Insider Cluster
| $13.60 awaiting T+1 | awaiting T+1 | — | $14.01 (+3.05%) |
|
Jun 12, 2026
today
|
Institutional Cluster
| $13.08 awaiting T+1 | awaiting T+1 | — | $14.01 (+7.15%) |
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $13.03 awaiting T+1 | awaiting T+1 | — | $14.01 (+7.52%) |
|
Jun 9, 2026
3d ago
|
S-3ASR
| $14.29 awaiting T+1 | awaiting T+1 | — | $14.01 (+1.93%) |
|
Jun 4, 2026
8d ago
|
Insider Cluster
| $15.01 awaiting T+1 | awaiting T+1 | — | $14.01 (−6.66%) |
|
Jun 4, 2026
8d ago
|
Insider Cluster
| $15.30 awaiting T+1 | awaiting T+1 | — | $14.01 (−8.43%) |
|
Jun 3, 2026
9d ago
|
8-K
| $15.07 $14.84 | ▼ −1.53% | ▼ −1.93% | $14.01 (−7.03%) |
|
Jun 1, 2026
11d ago
|
8-K
| $15.71 $14.86 | ▼ −5.41% | ▼ −5.56% | $14.01 (−10.82%) |
|
Apr 30, 2026
6w ago
|
8-K
| $16.12 $16.98 | ▲ +5.37% | ▲ +5.71% | $14.01 (−13.06%) |
|
Apr 17, 2026
8w ago
|
DEFA14A
| $25.12 $26.38 | ▲ +5.02% | ▲ +5.67% | $14.01 (−44.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access